Dépôt numérique
RECHERCHER

Phosphorylation of JAK2 by serotonin 5-HT(2A) receptor activates both STAT3 and ERK1/2 pathways and increases growth of JEG-3 human placental choriocarcinoma cell

Oufkir, Talal et Vaillancourt, Cathy ORCID logoORCID: https://orcid.org/0000-0003-0543-6244 (2011). Phosphorylation of JAK2 by serotonin 5-HT(2A) receptor activates both STAT3 and ERK1/2 pathways and increases growth of JEG-3 human placental choriocarcinoma cell Placenta , vol. 32 , nº 12. pp. 1033-1040. DOI: 10.1016/j.placenta.2011.09.005.

Ce document n'est pas hébergé sur EspaceINRS.

Résumé


Serotonin 5-HT(2A) receptor activation improves viability, increases DNA synthesis and activates JAK2-STAT3 and MEK1/2-ERK1/2 signalling pathways in JEG-3 human trophoblast choriocarcinoma cells. The goal of this study was to characterize the signal transduction cascade involved in 5-HT(2A) receptor-induced growth of JEG-3 cells. Selective 5-HT(2A) receptor agonist, DOI, induced JEG-3 cell growth was inhibited by the inhibitor of JAK2 (AG490), MEK1/2 (U0126), phospholipase C-β (PLC-β; U73122) and protein kinase C-β (PKC-β; Go6976)), whereas the selective phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) had no effect. Specific inhibitors of PLC-β, PKC-β and Ras (farnesylthiosalicylic acid) inhibit activation of ERK1/2, whereas the PKC-ζ inhibitor GF109203X had no effect. Interestingly, inhibition of JAK2 prevented DOI-induced phosphorylation of ERK1/2 whereas inhibition of ERK1/2 pathway had no effect on DOI-induced activation of STAT3. Taken together, our results demonstrate that both the JAK2-STAT3 and PLC-β-PKC-β-Ras-ERK1/2 signalling pathways are involved in the stimulation of JEG-3 cell growth mediated by DOI. Moreover, this study shows that activation of JAK2 by the 5-HT(2A) receptor is essential to activate both STAT3 and ERK1/2 signalling pathways as well as to increase JEG-3 choriocarcinoma cell growth and survival.

Type de document: Article
Mots-clés libres: 5-HT2A receptor; Serotonin; Cell signalling; Mitogen-activated kinase (MAPK); phospholipase C (PLC); Protein kinase C (PKC); Janus kinase (JAK)
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 27 mars 2024 15:23
Dernière modification: 27 mars 2024 15:23
URI: https://espace.inrs.ca/id/eprint/15011

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice